Unicycive therapeutics.

Mar 31, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, a patent protected, novel investigational phosphate-binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Dr. Shalabh Gupta, MD, founder, chairman of the board of directors and CEO of Unicycive Therapeutics Inc. Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist […]Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...Dr. Shalabh Gupta, MD, founder, chairman of the board of directors and CEO of Unicycive Therapeutics Inc. Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a …Oct 23, 2023 · About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is ...

Dr. Shalabh Gupta, MD, founder, chairman of the board of directors and CEO of Unicycive Therapeutics Inc. Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a …Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18 ...

Unicycive Therapeutics stock is dropping on an update from regulators.; The Food and Drug Administration (FDA) wants more data on its hyperphosphatemia in chronic kidney disease patients treatment.

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18 ... Nov 29, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ... Psychedelic therapy, also known as psychedelic-assisted psychotherapy (PAP), combines traditional talk therapy with a psychedelic substance, such as LSD, psilocybin, ayahuasca, or MDMA.

Unicycive Therapeutics is a biopharma company with development programs focused on two kidney dis... Treasure Global Inc. (Nasdaq: TGL) Treasure Global Inc. is a globally recognized e-commerce platform from Malaysia, offering technol...

Jun 29, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

Mar 6, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ... Unicycive Therapeutics (UNCY) invents and develop medications that make a meaningful difference in the lives of kidney patients and their caregivers. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...LOS ALTOS, Calif., July 13, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the pricing of its underwritten initial public offering of 5,000,000 units at a public offering price per unit of $5.00.Unicycive Therapeutics Inc (UNCY) $0.49 0.01 (2.47%) 15:59 EST UNCY Stock Quote Delayed 30 Minutes The 7 Most Undervalued Penny Stocks to Buy in October 2023.

Therapeutic Focus - Unicycive. We are a community of collaborators who thrive on connections and camaraderie. Currently, we are focused on developing new treatment options for patients with renal diseases, as kidney disease remains a major global health concern. Kidney disease remains a major global health concern and Unicycive (UNCY) is ... Mar 6, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ... When is Unicycive Therapeutics's earnings date? Unicycive Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 29th, 2024 based off last year's report dates. Learn more on UNCY's earnings history.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent ...Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.Unicycive Therapeutics, Inc; 2022. Oxylanthanum Carbonate (OLC) is an unapproved investigational new drug being developed. Contact Unicycive Therapeutics (UNCY) to …

Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS ...Mar 6, 2023 · LOS ALTOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for...

Unicycive Therapeutics is a biopharma company with development programs focused on two kidney dis... Treasure Global Inc. (Nasdaq: TGL) Treasure Global Inc. is a globally recognized e-commerce platform from Malaysia, offering technol...Dr. Shalabh Gupta, MD, founder, chairman of the board of directors and CEO of Unicycive Therapeutics Inc. Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist […]Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ...30 Oct 2023 ... 4 likes, 0 comments - b2i_digital on October 30, 2023: "Unicycive Therapeutics (Nasdaq: $UNCY), a B2i Digital Featured Company, ...Get the latest Unicycive Therapeutics Inc (UNCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Commenced Patient Dosing in MyPeak-1 TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Positive Phase 1 Data for TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at HFSA 2023 …Aug 14, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Investors - Unicycive. [WE DO NOT CONTROL THIS SECTION OF THE SITE. WE WILL CONNECT WITH THE THIRD PARTY BUT MAY NEED TO CREATE THE HEADER IMAGE. THIS COULD BE A MAGNIFYING GLASS MADE OUT OF DOTS.] [WE DO NOT CONTROL THIS SECTION OF THE SITE.Feb 2, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

Dec 1, 2023 · Unicycive Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for ...

Unicycive Therapeutics, Inc. (UNCY) SEC Filing 8-K Material Event for the period ending Tuesday, September 5, 2023. Home. SEC Filings. Unicycive Therapeutics, Inc. (UNCY) 8-K Material Event Wed Sep 06 2023; SEC Filings. UNCY Valuations. Intrinsic Value. Financial Stability. Financial Ratios. Insider Trades.

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, a patent protected, novel investigational phosphate-binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18 ...RedChip Companies will air a new interview with Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, on ...Aarvik Therapeutics is pursuing exciting molecules with an improved therapeutic index for several oncology targets by combining novel modular antibody platforms with multiple target mechanisms. Aarvik antibody platforms are readily manufacturable, scalable and versatile, and offer unlimited potential through modular design. ...Shalabh Gupta founded Unicycive Therapeutics, Inc., Biocycive, Inc. and Globavir Biosciences, Inc. He is Chairman, President & Chief Executive Officer at Unicycive Therapeutics, Inc. and Chief Executive Officer for Globavir Biosciences, Inc.Feb 27, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... LOS ALTOS, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney …TTOO. T2 Biosystems, Inc. Common Stock. $0.56 +0.1067 +23.54%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market ...

About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug …Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...Stock analysis for Unicycive Therapeutics Inc (UNCY:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.When is Unicycive Therapeutics's earnings date? Unicycive Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 29th, 2024 based off last year's report dates. Learn more on UNCY's earnings history.Instagram:https://instagram. air conditioning stocksmusical equipment insurancesotheby's montereyforex brokers in south africa Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference Jul 18, 2023 7:03am EDT Unicycive Therapeutics Announces … crm stock forcastlargest ria Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ... alrtf stock Therapeutic Focus · Pipeline · UNI-494 · Oxylanthanum Carbonate (OLC) · Investors ... Prior to joining Unicycive, he worked at Spectrum Pharmaceuticals for 15 ...Unicycive Therapeutics Report this profile About A physician by training and background - found my passion in bringing new technologies to… Experience Unicycive Therapeutics ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...